Literature DB >> 8150015

Measles vaccine: a 27-year follow-up.

M E Ramsay1, D Moffatt, M O'Connor.   

Abstract

In 1964, the Medical Research Council undertook a trial of measles vaccine in over 36,000 United Kingdom children; 9577 of whom received live vaccine, 10,625 received inactivated followed by live vaccines, and 16,328 acted as unvaccinated controls. Participants in this study have been followed to determine the long term protection from measles vaccine and follow-up data were available on 4194, 4638 and 274 respectively. During the 5-year period 1986-90, the protective efficacy of live measles vaccine has remained high at 87%, but the 95% confidence interval was wide (-43 to 99%) due to the small numbers of cases. Between 1976 and 1990, however, the overall efficacy of the live vaccine was 92% (95% confidence interval 86 to 95%) and there was no evidence of a decline in efficacy (P = 0.13) over the 15-year period. This study suggests that the protection from live measles vaccine persists for up to 27 years after vaccination, and that no change in the current United Kingdom measles immunization policy should be made on the grounds of waning immunity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150015      PMCID: PMC2271445          DOI: 10.1017/s0950268800057824

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  8 in total

1.  Measles, mumps, and rubella vaccine: time for a two stage policy.

Authors:  D S Sloan
Journal:  BMJ       Date:  1992-04-04

2.  Measles, mumps, and rubella vaccination.

Authors:  E Miller; D J Nokes; R M Anderson
Journal:  BMJ       Date:  1992-05-30

3.  Measles, mumps, and rubella vaccine: time for a two stage policy?

Authors:  H Carter; D Gorman
Journal:  BMJ       Date:  1992-03-07

4.  Measles, mumps, and rubella vaccination.

Authors:  A Hill
Journal:  BMJ       Date:  1992-03-21

5.  A seroepidemiologic study of a measles epidemic in a highly immunized population.

Authors:  C C Linnemann; T C Rotte; G M Schiff; J L Youtsey
Journal:  Am J Epidemiol       Date:  1972-03       Impact factor: 4.897

6.  Scandinavian model for eliminating measles, mumps, and rubella.

Authors:  E Rabo; J Taranger
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

7.  Measles outbreak among vaccinated high school students--Illinois.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1984-06-22       Impact factor: 17.586

8.  Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.

Authors:  B Dai; Z H Chen; Q C Liu; T Wu; C Y Guo; X Z Wang; H H Fang; Y Z Xiang
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

  8 in total
  5 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection.

Authors:  M Narita; S Yamada; Y Matsuzono; O Itakura; T Togashi; H Kikuta
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

Review 3.  Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review.

Authors:  Stephanie L Hughes; Shelly Bolotin; Sumaiya Khan; Ye Li; Caitlin Johnson; Lindsay Friedman; Andrea C Tricco; Susan J M Hahné; Jane M Heffernan; Alya Dabbagh; David N Durrheim; Walter A Orenstein; William J Moss; Mark Jit; Natasha S Crowcroft
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

5.  Measles outbreak investigation in a highly vaccinated community in the Centre region of Cameroon.

Authors:  Haddison C Eposi; Ngwafor A Randolph; Kagina M Benjamin
Journal:  J Public Health Afr       Date:  2021-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.